PegIFN alfa-2a

DRUG3 trials

Sponsors

ANRS, Emerging Infectious Diseases, Huashan Hospital, The Second Affiliated Hospital of Chongqing Medical University

Conditions

Chronic Hepatitis BHIV InfectionHepatitis BHepatitis C, Chronic

Phase 2

Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen

CompletedNCT01332955

ANRS, Emerging Infectious DiseasesHepatitis C, Chronic, HIV Infection

Start: 2011-04-01End: 2013-09-01Updated: 2026-04-02

Phase 4

Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy

CompletedNCT02594293

Huashan HospitalChronic Hepatitis B

Start: 2015-10-31End: 2022-09-30Updated: 2022-10-31

Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides

The Second Affiliated Hospital of Chongqing Medical UniversityHepatitis B

Start: 2015-12-31End: 2018-12-31Target: 196Updated: 2016-01-01

Related Papers

PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial.

2024-07-3110 citations

Telaprevir for HIV/Hepatitis C Virus-Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): An Open-Label, Single-Arm, Phase 2 Trial

Clinical Infectious Diseases2014-08-1828 citations